Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Cutoff Suppresses RNA Polymerase II Termination to Ensure Expression of piRNA Precursors.

Chen YA, Stuwe E, Luo Y, Ninova M, Le Thomas A, Rozhavskaya E, Li S, Vempati S, Laver JD, Patel DJ, Smibert CA, Lipshitz HD, Toth KF, Aravin AA.

Mol Cell. 2016 Jul 7;63(1):97-109. doi: 10.1016/j.molcel.2016.05.010. Epub 2016 Jun 9.

2.

Defect related emission versus intersystem crossing: blue emitting ZnO/graphene oxide quantum dots.

Vempati S, Celebioglu A, Uyar T.

Nanoscale. 2015 Oct 14;7(38):16110-8. doi: 10.1039/c5nr04461h. Epub 2015 Sep 15.

PMID:
26371542
3.

Brazilian scientist is part of elite group of researchers fighting cancer, obtains an unprecedented patent in the United States.

Katona DL, Vempati S, Savir OS.

Braz J Biol. 2015 Jan-Mar;75(1):256-8. doi: 10.1590/1519-6984.25014. No abstract available.

4.

Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL.

Stubbs MC, Kim W, Bariteau M, Davis T, Vempati S, Minehart J, Witkin M, Qi J, Krivtsov AV, Bradner JE, Kung AL, Armstrong SA.

Clin Cancer Res. 2015 May 15;21(10):2348-58. doi: 10.1158/1078-0432.CCR-14-1290. Epub 2015 Feb 16.

5.

Review of one-dimensional and two-dimensional nanostructured materials for hydrogen generation.

Babu VJ, Vempati S, Uyar T, Ramakrishna S.

Phys Chem Chem Phys. 2015 Feb 7;17(5):2960-86. doi: 10.1039/c4cp04245j.

PMID:
25536309
6.

Fluorescence from graphene oxide and the influence of ionic, π-π interactions and heterointerfaces: electron or energy transfer dynamics.

Vempati S, Uyar T.

Phys Chem Chem Phys. 2014 Oct 21;16(39):21183-203. doi: 10.1039/c4cp03317e. Epub 2014 Sep 8.

PMID:
25197977
7.

Role of zinc interstitials and oxygen vacancies of ZnO in photocatalysis: a bottom-up approach to control defect density.

Kayaci F, Vempati S, Donmez I, Biyikli N, Uyar T.

Nanoscale. 2014 Sep 7;6(17):10224-34. doi: 10.1039/c4nr01887g.

PMID:
25056654
8.

Selective isolation of the electron or hole in photocatalysis: ZnO-TiO2 and TiO2-ZnO core-shell structured heterojunction nanofibers via electrospinning and atomic layer deposition.

Kayaci F, Vempati S, Ozgit-Akgun C, Donmez I, Biyikli N, Uyar T.

Nanoscale. 2014 Jun 7;6(11):5735-45. doi: 10.1039/c3nr06665g. Epub 2014 Mar 24.

PMID:
24664354
9.

One-step synthesis of ZnO nanosheets: a blue-white fluorophore.

Vempati S, Mitra J, Dawson P.

Nanoscale Res Lett. 2012 Aug 21;7(1):470. doi: 10.1186/1556-276X-7-470.

10.

MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L.

Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV, Feng Z, Punt N, Daigle A, Bullinger L, Pollock RM, Richon VM, Kung AL, Armstrong SA.

Cancer Cell. 2011 Jul 12;20(1):66-78. doi: 10.1016/j.ccr.2011.06.010.

11.

CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes.

Reindl C, Quentmeier H, Petropoulos K, Greif PA, Benthaus T, Argiropoulos B, Mellert G, Vempati S, Duyster J, Buske C, Bohlander SK, Humphries KR, Hiddemann W, Spiekermann K.

Clin Cancer Res. 2009 Apr 1;15(7):2238-47. doi: 10.1158/1078-0432.CCR-08-1325. Epub 2009 Mar 10.

12.

H3K79 methylation profiles define murine and human MLL-AF4 leukemias.

Krivtsov AV, Feng Z, Lemieux ME, Faber J, Vempati S, Sinha AU, Xia X, Jesneck J, Bracken AP, Silverman LB, Kutok JL, Kung AL, Armstrong SA.

Cancer Cell. 2008 Nov 4;14(5):355-68. doi: 10.1016/j.ccr.2008.10.001.

13.

Transformation by oncogenic mutants and ligand-dependent activation of FLT3 wild-type requires the tyrosine residues 589 and 591.

Vempati S, Reindl C, Wolf U, Kern R, Petropoulos K, Naidu VM, Buske C, Hiddemann W, Kohl TM, Spiekermann K.

Clin Cancer Res. 2008 Jul 15;14(14):4437-45. doi: 10.1158/1078-0432.CCR-07-1873.

14.

AML1-ETO meets JAK2: clinical evidence for the two hit model of leukemogenesis from a myeloproliferative syndrome progressing to acute myeloid leukemia.

Schneider F, Bohlander SK, Schneider S, Papadaki C, Kakadyia P, Dufour A, Vempati S, Unterhalt M, Feuring-Buske M, Buske C, Braess J, Wandt H, Hiddemann W, Spiekermann K.

Leukemia. 2007 Oct;21(10):2199-201. Epub 2007 Jul 12. No abstract available.

PMID:
17625612
15.

Arginine 595 is duplicated in patients with acute leukemias carrying internal tandem duplications of FLT3 and modulates its transforming potential.

Vempati S, Reindl C, Kaza SK, Kern R, Malamoussi T, Dugas M, Mellert G, Schnittger S, Hiddemann W, Spiekermann K.

Blood. 2007 Jul 15;110(2):686-94. Epub 2007 Mar 26.

16.

Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML.

Reindl C, Bagrintseva K, Vempati S, Schnittger S, Ellwart JW, Wenig K, Hopfner KP, Hiddemann W, Spiekermann K.

Blood. 2006 May 1;107(9):3700-7. Epub 2006 Jan 12.

17.

Grand unification of quark and lepton flavor changing neutral currents.

Ciuchini M, Masiero A, Silvestrini L, Vempati SK, Vives O.

Phys Rev Lett. 2004 Feb 20;92(7):071801. Epub 2004 Feb 17.

PMID:
14995839
18.

Decreased heart-period variability in patients with panic disorder: a study of Holter ECG records.

Yeragani VK, Sobolewski E, Igel G, Johnson C, Jampala VC, Kay J, Hillman N, Yeragani S, Vempati S.

Psychiatry Res. 1998 Mar 20;78(1-2):89-99.

PMID:
9579705
19.

Fractal dimension of heart rate time series: an effective measure of autonomic function.

Yeragani VK, Srinivasan K, Vempati S, Pohl R, Balon R.

J Appl Physiol (1985). 1993 Dec;75(6):2429-38.

PMID:
8125861

Supplemental Content

Loading ...
Support Center